Prof. Andreas Mackensen received his approbation as physician and MD degree from the

University of Freiburg in 1988. After an internship at the University of Freiburg, he was a

postdoctoral fellow from the DFG between 1991 and 1993 at the Institute Gustave Roussy,

Villejuif. His research focus was on the characterization of tumor-specific immune responses

in regressive melanoma. Back in Freiburg, he completed his training as a

hematologist/oncologist and habilitated in Internal Medicine 1998. From 1999-2007 A.

Mackensen was Professor (C3) for Hematology/Oncology at the University of Regensburg.

He initiated one of the first european phase I clinical trials with adoptively transferred

tumor-reactive T cells in advanced malignant melanoma. In 2007, A. Mackensen became full

professor for Hematology/Oncology and Director of the Dept. of Internal Medicine 5 –

Hematology/Oncology at the University of Erlangen. A. Mackensen is a principal investigator

in different investigator-initiated cell-based immunotherapy studies with CAR T-cells for

patients with hematologic diseases, solid tumors, and autoimmune diseases. Since 2020,

Andreas Mackensen is the director of the Bavarian Center for Cancer Research (BZKF).